Crescent Diagnostics (Ireland) Ltd., a medical diagnostics company, engages in the development of a testing platform for novel biomarkers to predict disease risk. It offers Bone Quality Test, an osteoporosis screening tool that enables clinicians to identify those who are at high risk of suffering a hip fracture. The company sells its products through pharmacies in the United Kingdom. Crescent Diagnostics (Ireland) Ltd. was founded in 2004 and is based in Dublin, Ireland.
University College Dublin
Founded in 2004
Crescent Diagnostics Ltd Launches Osentia Test, Enable People to Assess Risk of Suffering Fragility Fracture
Mar 10 14
Crescent Diagnostics Ltd. has launched Osentia, a new convenient screening test which identifies those at risk of fragility fracture by analysing finger or toe nail clippings. Launching in the UK, Osentia is available online and will shortly be available direct from pharmacies. The test enables consumers to identify their level of risk of suffering a fragility fracture due to osteoporosis. Using this information, consumers can initiate long term lifestyle changes and access appropriate therapeutic intervention, which can help avoid serious osteoporosis-related fractures in later life. With more than 30 million people at risk of the disease in the EU, early identification is important. Osteoporosis causes bones to become weak and fragile, and more likely to fracture. People are often unaware of the condition of their bones, as the disease displays no symptoms. As the bones affected are most frequently the wrist, spine or hip bones, any fracture can lead to considerable pain, surgery and a lengthy rehabilitation. According to the UK's National Osteoporosis Society, one in two women and one in five men over the age of 50 will fracture a bone, mainly due to poor bone health. In the UK, almost three million people are estimated to have osteoporosis, costing the NHS GBP 2.3 billion a year. The Osentia screening process measures the protein keratin in nail clippings, which is used as a surrogate biomarker for collagen, a key indicator of bone strength. Keratin abnormality can indicate a risk of developing osteoporosis. Having purchased the test, customers send a nail clipping to Crescent's laboratory where it is analysed. The customer's result will be presented as one of three risk profiles; green, amber or red. A green result indicates a low risk of suffering a fragility fracture, but a retest within two years is recommended. An amber result indicates a moderate risk of suffering a fragility fracture. In this instance it is recommended that the consumer should increase their consumption of cheese and milk in their diet, avoid smoking and drinking, increase their level of weight-bearing exercise and consider adding calcium and vitamin D supplements to their diet to promote and maintain healthy bones. A red result is indicative of a high risk of fracture and those in this category are advised to visit their GP for a consultation and assessment. In addition to the Osentia test, customers will also complete a lifestyle questionnaire, which is used to more fully assess their risk of fragility fracture.
Crescent Diagnostics Ltd. Presents at Investment-In-Innovation (IN3) Medical Device 360 Degrees Dublin, Apr-18-2013 10:20 AM
Apr 8 13
Crescent Diagnostics Ltd. Presents at Investment-In-Innovation (IN3) Medical Device 360 Degrees Dublin, Apr-18-2013 10:20 AM. Venue: The Shelbourne Dublin, Dublin, Ireland.